Cargando…

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment

In order to meet the challenges in data evaluation and comparability between studies in multiple myeloma (MM) minimal residual disease (MRD) assessment, the goal of the current study was to provide a step-by-step evaluation of next-generation sequencing (NGS) and multicolor flow cytometry (MFC) data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kriegsmann, Katharina, Hundemer, Michael, Hofmeister-Mielke, Nicole, Reichert, Philipp, Manta, Calin-Petru, Awwad, Mohamed H.S., Sauer, Sandra, Bertsch, Uta, Besemer, Britta, Fenk, Roland, Hänel, Mathias, Munder, Markus, Weisel, Katja C., Blau, Igor W., Neubauer, Andreas, Müller-Tidow, Carsten, Raab, Marc S., Goldschmidt, Hartmut, Huhn, Stefanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464347/ https://www.ncbi.nlm.nih.gov/pubmed/32824635 http://dx.doi.org/10.3390/cancers12082322

Ejemplares similares

Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM
por: Kriegsmann, Katharina, et al.
Publicado: (2022)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

P383: THE NEXT-GENERATION SEQUENCING (NGS) BASED MRD ASSESSMENT COULD BETTER PREDICT RELAPSE THAN MULTIPARAMETER FLOW CYTOMETRY (MFC) IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Yan, Nan, et al.
Publicado: (2023)

P879: EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA
por: Huhn, S., et al.
Publicado: (2022)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Cell-based immunotherapy approaches for multiple myeloma
por: Kriegsmann, Katharina, et al.
Publicado: (2018)

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
por: Salwender, Hans, et al.
Publicado: (2019)

MFC programming
por: Feuer, Alan R
Publicado: (1997)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL
por: Mai, E. K., et al.
Publicado: (2022)

Vidjil add‐on for MRD quantification of samples processed using the EuroClonality‐NGS protocol
por: Giusti, Guilherme Navarro Nilo, et al.
Publicado: (2023)

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
por: John, Lukas, et al.
Publicado: (2023)

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
por: Schmitt, Michael, et al.
Publicado: (2016)

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Larribère, Lionel, et al.
Publicado: (2021)

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
por: Loo, Sun, et al.
Publicado: (2022)

Extending the MFC library : add useful reusable features to the Microsoft foundation class library
por: Schmitt, David A.
Publicado: (1996)

P1263: A SENSITIVE NGS ASSAY TO DETECT MEASURABLE RESIDUAL DISEASE (MRD) IN B-CELL LYMPHOPROLIFERATIVE DISEASES
por: Hebert, L., et al.
Publicado: (2022)

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
por: Li, Yonghong, et al.
Publicado: (2023)

PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.
por: Sánchez-Redondo, Noemí Álvarez, et al.
Publicado: (2023)

Visual C++ how-to: the definitive MFC problem solver
por: Stanfield, Scott, et al.
Publicado: (1995)

Teach yourself MFC library programming in 21 days
por: Shaw, Robert, et al.
Publicado: (1995)

Investigation of ceramic MFC stacks for urine energy extraction
por: Tremouli, Asimina, et al.
Publicado: (2018)

PVDF-Modified Nafion Membrane for Improved Performance of MFC
por: Fan, Liping, et al.
Publicado: (2020)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Microbial fuel cell scale-up options: Performance evaluation of membrane (c-MFC) and membrane-less (s-MFC) systems under different feeding regimes
por: Walter, Xavier Alexis, et al.
Publicado: (2022)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Mfc1 is a novel copper transporter during meiosis
por: Beaudoin, Jude, et al.
Publicado: (2012)

The influence of electrode spacing on the performance of bioretention cell coupled with MFC
por: Ya-Jun, Wang, et al.
Publicado: (2021)

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
por: Hose, Dirk, et al.
Publicado: (2019)

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
por: Leypoldt, Lisa B., et al.
Publicado: (2021)

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2020)

Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2021)

Software application development: a visual C++, MFC, and STL tutorial
por: Fox, Bud, et al.
Publicado: (2013)

An MFC-Based Online Monitoring and Alert System for Activated Sludge Process
por: Xu, Gui-Hua, et al.
Publicado: (2014)

Resilience and limitations of MFC anodic community when exposed to antibacterial agents
por: Obata, Oluwatosin, et al.
Publicado: (2020)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Novel immunotherapies in multiple myeloma – chances and challenges
por: Rasche, Leo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kmba19vh8ic97io7nq1bn4bhoc